April, 2008
Apath Signs
Exclusive Agreement with Toray Industries, Inc.
Apath, LLC has completed an exclusive
agreement with Toray Industries, Inc in order to provide non-exclusive
sublicenses for HCV JFH-1 technology.
September, 2007
Apath Receives Grant from the
National Institutes of Health.
Apath, LLC
has received a 6 month, $100,713 award from the National Institutes of
Health for the project titled “The in vitro hepatitis C virus infection
system as a drug discovery tool". More than 170 million people are infected
with hepatitis C virus (HCV). At an estimated 3% of the world’ population,
the HCV epidemic exacts a heavy toll on public health systems worldwide. The
majority of infected patients remain infected for life and a significant
percentage of HCV-infected patients ultimately progress to cirrhosis, liver
failure, or hepatocellular carcinoma (liver cancer). Efforts to develop
better therapies for HCV have been hampered by difficulties in propagating
the virus in cell culture and the lack of small animal models. The
development of HCV replicons several years ago greatly facilitated the
testing of small molecule inhibitors of specific HCV targets. Recently HCV
cDNA clones have been developed which can be used to launch the full viral
replication cycle in cell culture (termed HCVcc, for infectious HCV in cell
culture). There remain, however, some shortfalls: 1) HCVcc produces
relatively low virus titers in cell culture, 2) it is genotype 2a, which is
distinct from the genotype 1 strains of HCV that are the main cause of liver
disease in most regions of the world and the most difficult to treat, and 3)
there is a dearth of culture protocols and reagents needed to facilitate
vaccine and antiviral research and development. Apath has exclusively
licensed the rights to develop, use and market the infectious HCV system
developed at Rockefeller University. Apath will use the funds provided by
this award to develop the HCVcc system as a useful tool for drug and vaccine
development. Our proposal is predicated upon the strong published data
showing that HCVcc can replicate in cell culture and produce infectious
virus with similar physical properties to natural HCV isolates, and can be
inhibited by IFNα and several HCV-specific antiviral compounds. Our central
hypothesis is that the HCVcc system can be developed into a better drug
discovery and vaccine development tool by enhancing virus titers and by
providing useful reagents. Our rationale for these studies is that their
successful completion would provide a better HCVcc system which will be
marketed to the pharmaceutical industry via non-exclusive licenses, and be
made available to the HCV research community.
September, 2007
Apath Receives Grant from the
National Institutes of Health.
Apath, LLC has received a 3 year, $2.1 million dollar award from the
National Institutes of Health for the project titled “Developing small
molecule therapeutics for West Nile virus
(WNV), a member of the Flaviviridae family. The Flavivirus genus of
the Flaviviridae family of viruses contains important human
pathogens, such as, Dengue, Yellow Fever, West Nile, St. Louis encephalitis,
Japanese encephalitis, and tick-borne encephalitis viruses. Several of
these viruses are listed by the NIH and CDC as possible agents of
bioterrorism. The need for safe and effective, broad-spectrum and specific
antivirals against these highly pathogenic agents is a key priority. In
collaboration with Dr. Michael Diamond of Washington University in St.
Louis, Apath identified several candidate lead compounds in a proprietary
viral replicon-based screening platform and confirmed their inhibitory
activity in WNV infection assays in cell culture. Funds from this award
will be used to bring these potential anti-viral lead compounds through a
preclinical drug development program. This work will have several phases
and includes: (a) Medicinal chemistry studies with an emphasis on lead
optimization in which structure-activity-relationships (SAR) are used to
enhance potency and drug-like properties. (b) Preclinical toxicology and
pharmacokinetic (PK) studies will be performed in small animals. These
studies will predict how the antiviral compounds distribute and behave in
vivo and will include an analysis of cytotoxicity, solubility, metabolic
stability, cell permeability, and plasma protein binding. (c) Compounds with
acceptable toxicity and PK profiles will be tested in efficacy studies using
a well-characterized mouse model of WNV infection. (d) The ability of our
small molecule anti-WNV compounds to synergize with a neutralizing humanized
monoclonal antibody to generate a more potent combination therapeutic
regimen will be studied. (e) For the lead compounds with the greatest WNV
anti-viral potential in vivo, virological studies will be performed
to define the mechanism of action. It is expected that these studies will
result in the production of an antiviral drug for future clinical trials to
determine safety and efficacy against WNV, and possibly other flavivirus
infections.
March, 2006
Apath Receives Phase II
Department of Defense Contract.
Apath, LLC has received a 2 year, $750,000
Phase II contract from the Department of Defense for the project titled "Filovirus
drug discovery using novel combinations of approved drugs". Ebola and
Marburg viruses, the only filoviruses, cause an acute hemorrhagic fever
syndrome which has a high mortality rate and poses a significant
bio-terrorism threat. There are currently no therapeutic agents available to
treat filovirus infections and the development of such drugs is important
for bio-defense. Apath has developed a novel screening method that can
identify inhibitors of replication of Ebola virus, but which does not
involve using infectious virus. This proposal focuses on a strategy to
discover combinations of drugs that have novel anti-filovirus activity. The
Apath screening method is very amenable to identifying drug combinations
that inhibit these deadly viruses.
September, 2005
Apath founder, Dr. Charles M.
Rice, elected to the National Academy of Sciences.
The National Academy of Sciences announced the
election of 72 new members and 18 foreign associates from 14 countries in
recognition of their distinguished and continuing achievements in original
research. The election was held this morning during the business session of
the 142nd annual meeting of the Academy. Election to membership in the
Academy is considered one of the highest honors that can be accorded a U.S.
scientist or engineer. Those elected today bring the total number of active
members to 1,976.
Article
September, 2005
Apath founder, Dr. Charles M.
Rice, develops infectious hepatitis C virus.
A team of researchers led by Apath’s founder
at The Rockefeller University has produced for the first time an infectious
form of the hepatitis C virus (HCV) in laboratory cultures of human cells.
Article
May, 2005
Apath Receives Department of
Defense Contract
Apath, LLC has received a ten month, $100,000
contract from the Department of Defense for the project titled "Filovirus
drug discovery using novel combinations of approved drugs ". The goal of
this proposal is find novel combinations of approved drugs for the treatment
and/or prevention of infection with Ebola and Marburg viruses which cause an
acute hemorrhagic fever syndrome which has a high mortality rate and poses a
significant bio-terrorism threat. There are currently no therapeutic agents
available to treat filovirus infections and the development of such drugs is
important for bio-defense. Apath has developed a novel, cell-based,
infection-independent screening method that is based on replication of an
Ebola virus minigenome. This proposal focuses on a strategy of combining
existing drugs to discover combinations that have novel anti-filovirus
activity. The Apath screening method is very amenable to identifying drug
combinations that inhibit EBOV replication. The number of possible
combinations of approved drugs, however, is enormous and so a recently
described system will be used that identifies combinations of compounds that
produce novel activity. This method streamlines the process of defining
chemical relationships to enable the discovery of combinations of drugs that
exhibit novel synergistic activity. The use of a library of approved drugs,
all of which possess biologically activity and bioavailability, should
facilitate the development of a therapeutic drug combination because they
have desirable pharmaceutical properties.
February, 2005
Apath Receives a Project
Bioshield Grant
Apath, LLC has received an eighteen month,
$1,350,000 Grant from the National Institute of Allergy and Infectious
Diseases (NIAID) of the National Institutes of Health for the proposal
titled "Therapeutics for Ebola virus". The award is funded under the Project
Bioshield Act of 2004. The goal of this proposal is to advance the
development of EBOV inhibitors that Apath will identify in a proprietary
screening assay and confirm in viral assays performed at the United States
Army Medical Research Institute of Infectious Diseases (USAMRIID) in Fort
Detrick Md. Anti-EBOV lead compounds will be taken through a preclinical
program of absorption, distribution, metabolism, elimination (ADME),
toxicology (Tox), and pharmacokinetic (PK) studies in preparation for an
eventual investigational new drug (IND) application to the FDA. It is
expected that these studies will result in the production of antiviral drugs
for future clinical trials to determine safety and efficacy against EBOV
infection.
Article
November, 2004
Apath selected for NIH
Commercialization Assistance Program
Apath was selected to participate in the NIH
Commercialization Assistance Program (NIH-CAP). This program is aimed at
helping commercialize products, services, or technology, resulting from the
SBIR research grants and contracts awarded to companies. Selection was based
on the quality of the technical and business information in the application.
About thirty companies will be participating in each workshop. This program
is designed to help some of the nation’s most promising life science startup
companies develop their commercial business. The CAP will begin in November,
2004 and will be composed of training workshops, individual mentoring and
consulting sessions, and public events in which companies present their
technologies to the biomedical and biotechnology investment communities,
potential strategic partners, and licensees. The NIH- CAP was kicked off
with a series of regional one-day workshops. Paul D. Olivo, M.D., Ph.D.,
President and Chief Scientific Officer at Apath attended the workshop at the
offices of Latham & Watkins in the Sears Tower in Chicago on November 12,
2004. In April 2005 Larta will organize and host a workshop to finalize
individual alliance, licensing, or regulatory packages, and to work on
business presentations.
Article
November, 2004
Focus On The Flu
The National Institutes of Health (NIH) has
recognized the research Apath is doing to promote improved diagnosis of
influenza virus infection. The web site Focus on the Flu
(http://www2.niaid.nih.gov/newsroom/focuson/flu04/)published by the National
Institute of Allergy and Infectious Diseases (NIAID)highlights work being
done by Apath (http://www2.niaid.nih.gov/Newsroom/FocusOn/Flu04/olivo.htm)
in collaboration with Dr. Andrew Pekosz at Washington University and with
Diagnostic Hybrids, Inc. in Athens, Ohio. Apath received a two and a half
year 'Fast Track' (combined Phase I and Phase II) SBIR award from the NIH in
March 2004 entitled Transgenic indicator cells for influenza virus.
Article
November 18, 2004
Nucleonics Licenses Key
Apath Technology for Use in Hepatitis C Therapeutic
Apath, LLC and Nucleonics, Inc.have entered
into a licensing agreement in which Nucleonics has received a non-exclusive
license to Apath's patented technology related to the 3' non-translated
region of the Hepatitis C viral genome, which Nucleonics is using as a
target in its development of an expressed RNAi therapeutic against Hepatitis
C. The Hepatitis C virus 3' NTR was discovered by Dr. Charles Rice's lab
while he was a professor at Washington University in St. Louis and Apath,
LLC has an exclusive license from Washington University to the technology.
Article
July 15, 2004
NIH Awards Apath Small
Business Technology Transfer (STTR)
Grant
Apath, LLC has received a two year, $741,038,
Phase I Grant from the Small Business Innovation Research Program from the
National Institute of Allergy and Infectious Diseases (NIAID) of the
National Institutes of Health for the proposal titled “Molecular tools for
Bunyavirus antiviral screening”. The award is from the Small Business
Biodefense Program and the vehicle of the award is the Small Business
Technology Transfer (STTR) program. STTR awards are similar to SBIR awards,
but the STTR Program requires research partners at universities and other
non-profit research institutions to have a formal collaborative relationship
with the small business concern. Apath is partnering with Dr. Andrew Pekosz,
Assistant Professor of Molecular Microbiology at Washington University.
Apath and Dr. Pekosz will collaborate to develop molecular tools to help
find antiviral drugs to treat bunyaviruses which includes viruses that cause
encephalitis, hemorragic fevers, and the hanta pulmonary syndrome. A number
of bunyaviruses are listed by the NIH and CDC as potential bioterrorism
agents.
Abstract
July 1, 2004
NIH Awards Apath Small
Business Biodefense
Grant
Apath, LLC has received a two year, $958,581,
Phase I Grant from the Small Business Innovation Research Program from the
National Institute of Allergy and Infectious Diseases (NIAID) of the
National Institutes of Health for the proposal titled “Replicon-based
screening for inhibitors of alphaviruses”. The award is from the Small
Business Biodefense Program. Apath will use its proprietary cell-based assay
to identify small molecule inhibitors of alphaviruses which includes certain
equine encecphalitis viruses which are listed by the NIH and CDC as
potential bioterrorism agents.
Abstract
March, 2004
NIH Awards Apath Fast Track SBIR
Grant
Apath, LLC has received a three
year $799,702 combined Phase I/Phase II (Fast Track) award from the Small
Business Innovation Research Program from the National Institute of Allergy
and Infectious Diseases (NIAID) for the proposal titled “Transgenic
indicator cells for influenza virus”. The overall goal is to develop tools
to diagnose influenza virus infections which are a major cause of endemic
and epidemic respiratory infections worldwide. In Phase I Apath will develop
transgenic cell lines that express a reporter gene in response to influenza
virus. Apath will use these cell lines to promote the development of
antivirals against influenza virus. In addition, these cell lines will form
the basis of an influenza detection test which will be developed in Phase II
in collaboration with Diagnostic Hybrids, Inc. (DHI, Athens, OH)
DHIusa.com,
and modeled after an existing FDA-approved test for herpes simplex virus
(ELVIS-HSV) currently sold and marketed by DHI.
Abstract
March 1, 2004
NIH Awards Apath Phase II SBIR
Grant
Apath, LLC has received a two
year, $750,000, Phase II Grant from the Small Business Innovation Research
Program from the National Institute of Allergy and Infectious Diseases (NIAID)
for the proposal titled “Indicator cells for antiviral screening for
filoviruses”. Apath will use its proprietary cell-based assay to identify
small molecule inhibitors of Ebola virus. The overall goal is to develop
better treatments for Ebola virus which is a cause of a highly fatal viral
hemorrhagic fever syndrome and a potential bioterrorism agent.
Abstract
February, 2004
Apath receives award
from Midwest Regional Center of Excellence
Apath, LLC received a
$55,000 Developmental Project Grant from the Midwest Regional Center of
Excellence in Biodefense and Emerging Infectious Diseases at Washington
University. The project title is “Peptide inhibitors of VP30 of Ebola
virus”. The project objective is to identify an inhibitor of Ebola virus (EBOV)
that targets the viral protein 30 (VP30) a transcriptional transactivator.
... The award period is March 2004 through Feb 2005.
Abstract
January 29, 2004
Tripos Selects Apath as
Recipient of Technology Award
International Competition Rewards High-Potential Research With Access to
Compounds and Software for Rapid Drug Discovery ST. LOUIS — Jan. 29, 2004 —
Tripos, Inc. (Nasdaq: TRPS), a leading provider of drug discovery chemistry
and informatics products, today announced the BioBelt-region recipient of
its Hits-to-Leads program. The proposal from Apath, LLC, one of only three
research organizations chosen to date worldwide, holds promise for important
advances in the search for broad-spectrum antiviral drug therapies.
Tripos
is a leading provider of drug discovery chemistry and related informatics
technology. The company’s Hits-to-Leads program grants proprietary products
and services to overcome challenges faced by many researchers — lack of
access to a wide array of compounds and the software to efficiently scan and
track potential leads — without a major investment in infrastructure. “Our
goal is to accelerate drug discovery with organizations that have proven
their potential to find important medicines to improve the quality of human
life,” said Peter Hecht, Ph.D., senior vice president of discovery research
operations at Tripos.
Apath, an early-stage drug discovery company based in
St. Louis’ Nidus Center for Scientific Enterprise, is focused on the
development of broad-spectrum antiviral agents for RNA viruses, which today
are poorly treatable or entirely untreatable with currently available
medications.
“Tripos’ efficient tools will allow us to more quickly identify
potential drugs to combat viruses that plague humans across the globe,” said
Paul D. Olivo, M.D. and Ph.D., president and chief scientific officer of
Apath. “This partnership enhances our ability to prioritize criteria and
promote our efforts to identify broad spectrum antiviral agents — especially
those associated with respiratory syncytial virus (RSV), West Nile virus,
yellow fever, dengue, Ebola and Marburg viruses.”
Apath will receive
compounds, proprietary screening software and a customized data analysis
report. Depending on scope of application, the awards are estimated to be
worth at least $80,000 each, and include these resources:
•
LeadScreen™:
50,000 high-quality drug-like screening compounds
• SARNavigator™: a desktop
data analysis technology
• Customized report: Tripos’ scientists working
closely with the winners will develop a customized data analysis report.
About Apath, L.L.C.
Apath, L.L.C. is a privately-held drug discovery company
with unique technology and capabilities in viral biology, with a focus on
the discovery and development of broad-spectrum antiviral therapeutics for
RNA viruses. RNA viruses account for the majority of human viral pathogens,
and include diseases that cause a significant level of morbidity/mortality
such as Hepatitis-C (HCV), Respiratory Syncytial Virus (RSV), Influenza, and
various hemorrhagic fever viruses such as Ebola and Marburg. Apath’s
scientific staff has a proven track record and comprehensive expertise in
virology and molecular biology. In addition, the company owns or controls
key intellectual property and proprietary know-how in the RNA viral field,
as well as a screening platform uniquely suited to the identification of
broad-spectrum antiviral inhibitors. Apath is located at the Nidus Center
for Scientific Enterprise, a state-of-the-art technology incubator located
in St. Louis, Mo.
About Tripos, Inc.
Tripos (Nasdaq: TRPS) combines
leading-edge technology and innovative science to deliver consistently
superior chemistry-research products and services for the biotechnology,
pharmaceutical and other life science industries. Tripos partners with
clients to accelerate and improve the creation of life-enhancing products.
Within Tripos’ Discovery Informatics (DI) business, the company provides
software products and consulting services to develop, manage, analyze and
share critical drug discovery information. Within Tripos’ Discovery Research
(DR) business, Tripos’ medicinal chemists and research scientists partner
directly with clients in their research initiatives, leveraging
state-of-the-art information technologies and research facilities.
Headquartered in St. Louis, Mo., Tripos spans the world with global research
operations and an international client base. Further information on Tripos
can be found at
Tripos.com.
Saint Louis Business Journal Link
September 1, 2003
New NIH
Phase
I grant For Apath
Apath, LLC has received a six month,
$100,000, Phase I Grant from the Small Business Innovation Research Program
from the National Institute of Allergy and Infectious Diseases (NIAID) for
the proposal titled “Multiplexed Gene Assays by Microtiter Plate Microarrays”.
Apath will collaborate with ProteoPlex to develop a microarray technology
based on microtiter plates that will allow many samples to be queried for
expression of a defined number (10-100) of genes in a high throughput
format. This will assist Apath in characterizing its lead compounds and will
form the basis of a research tool that Proteoplex will develop for the drug
discovery industry.
Abstract
May 15, 2003
Apath receives Phase
I SBIR Grant From NIH
Apath, LLC has received a six month,
$100,000, Phase I Grant from the Small Business Innovation Research Program
from the National Institute of Allergy and Infectious Diseases (NIAID) for
the proposal titled “Construction of a Respiratory Syncytial Virus replicon”.
The goal of this award is to develop a novel "replicon" system for screening
potential antiviral compounds. This RSV replicon will also be valuable for
genetic studies of RSV and in efforts to use RSV as a vector.
Abstract
April 30, 2003
NIH awards Apath Phase
II SBIR grant
Apath, LLC has received a two year,
$750,000, Phase II Grant from the Small Business Innovation Research Program
from the National Institute of Allergy and Infectious Diseases (NIAID) for
the proposal titled “Screening for anti-RSV compounds with minigenome
indicators cells”. Apath will use its proprietary cell-based assay to
identify small molecule inhibitors of respiratory syncytial virus (RSV) to
develop better treatments for this virus which is a major cause of pneumonia
in infants.
Abstract
April 30, 2003
Apath, LLC a finalist in the
2003 St. Louis Business Journal Technology Awards!
Apath, LLC was selected as one of nine
finalists of the 2003 St. Louis Business Journal Technology Awards for 2003.
A panel of judges, consisting of scientists and technology experts from
Washington University, Saint Louis University and other members of the
scientific community, considered impact, scope, complexity and innovation of
the developed technology as criteria to select the winners from over 70
nominations. The awards ceremony was held April 10, 2003 at the St. Louis
American Theater. The program was sponsored by Thompson Coburn LLP and the
DESCO Group.
News Link
January 23, 2003
Apath completes deal to access
novel natural product chemical library
Apath has
signed a collaboration with BioProspect Limited (West Perth, Australia) to
discover novel compounds that could lead to treatments for human viral
diseases. Under the agreement Apath will access BioProspect’s unique
Natural Plant Extract Library and will screen these extracts against their
proprietary screening platform. BioProspect will then use its expertise in
natural product chemistry to identify any biologically active compounds.
BioProspect Chief Executive Officer, Selwyn Snell said, “We are extremely
excited to be working with Apath. Their technology in the area of HCV and
associated viruses is unique in the world of medicine.”
BioProspect News Article
BioProspect will
receive license fees for the supply of extracts under the agreement, and
further payments on completion of key development milestones. BioProspect
will also receive royalty payments on any commercialized products developed
from its extracts.
(BioProspect.com)
Apath’s
President and Chief Scientific Officer, Dr. Paul D. Olivo, said, “The
opportunity to work with BioProspect offers us a unique opportunity to
discover novel compounds for our antiviral drug discovery program.
BioProspect’s natural product library combines novel plant sources with
their unique capabilities to identify and isolate the active small molecules
in their plant extracts.
September 30, 2002
Apath Receives Subcontract from Washington University to perform collaborative
work on an National Institutes of Health Grant
Apath, LLC received a $1,409,000 subcontract from Washington University in St.
Louis as part of a National Institutes of Health sponsored collaborative project
between Apath and Dr. Michael Diamond of Washington University School of
Medicine. Apath will utilize subgenomic West Nile Virus (WNV) replicons as a
screening tool to identify small molecule inhibitors of WNV replication. Dr.
Diamond received the five year award for the proposal titled, Development of
Novel Antiviral Agents VS West Nile Virus.
Abstract
September 26, 2002
Apath, LLC a top 50 technology company in the
St. Louis Region
Apath,
LLC is selected as one of the top 50 technology companies in the St. Louis
region. Each year since 1996, the RCGA and Deloitte & Touche have presented
the St. Louis Regional Technology Fast 50 Awards to salute the region’s 50
fastest-growing high tech companies. In 2002, the Fast 50 awards program
evolved into the St. Louis Regional Technology Top 50 program, specifically
recognizing industry leadership in the region’s distinctive high tech
clusters; information technology, advanced manufacturing and life sciences.
The 2002 awards dinner will be presented at the St. Louis Science Center on
September 26, 2002.
Link
September 15, 2002
Apath Receives Grant From The National
Institutes of Health’s Institute of
Allergy and Infectious Diseases
Apath,
LLC received a two year, $375,000, Grant from the National Institutes of
Health’s Institute of Allergy and Infectious Diseases for the proposal
titled “Screening for antivirals against flaviviruses”. The goal of this
project is to identify compounds with antiviral activity against
flaviviruses such as yellow fever virus and dengue virus, using incomplete
viral genomes to identify inhibitors of any biochemical pathway involved in
viral genome replication. Apath was awarded this grant after responding to
a request for applications from the ‘Rapid Response Grant Program on
Bioterrorism-Related Research’ (RRGP-BTRR) released by the NIH on Dec 5,
2001.
Abstract
August, 15, 2002
Apath Receives Phase II Grant From The Small
Business Innovation Research Program From The National Institutes of Health
Apath,
LLC received a two year, $750,000, Phase II Grant from the Small Business
Innovation Research Program from the National Institutes of Health’s
Institute of Allergy and Infectious Diseases for the proposal titled
“Antiviral Screening Assays Based on HCV Replicons”. The goal of this award
is to use a cell-based assay to identify small molecule inhibitors of
hepatitis C virus toward the overall goal of developing better treatments
for this virus which is a major cause of chronic liver disease.
Abstract
August 1, 2002
Apath Receives Phase I Grant From The Small
Business Innovation Research Program From The National Institutes of
Health’s Institute of
Allergy and Infectious Diseases
Apath, LLC
received a 6 month, $100,000, Phase I Grant from the Small Business
Innovation Research Program from the National Institutes of Health’s
Institute of Allergy and Infectious Diseases for the proposal titled
“Indicator cells for antiviral screening for filoviruses”. The goal of this
project is to develop the commercial potential of a cell-based assay to
screen for compounds with antiviral activity against filoviruses viruses
using incomplete viral genomes to identify inhibitors of any biochemical
pathway involved in viral genome replication.
Abstract
May
2002
Apath Presents at 2002 InvestMidwest Venture
Capital Forum
Apath, LLC, was chosen to
be among a select group of Missouri companies seeking venture capital to
present at the upcoming InvestMidwest Venture Capital Forum to be held at
the Ritz Carlton in Clayton, MO. Apath is a privately held drug discovery
company with a focus on RNA viruses such as hepatitis C (HCV).
InvestMidwest Forum
March 15, 2002
NIH Awards Apath a Phase I Grant
Apath, LLC received a 6 month, $100,000, Phase
I Grant from the Small Business Innovation Research Program from the
National Institutes of Health’s Institute of Allergy and Infectious Diseases
for the proposal titled “Antiviral Screening against Multiple Viruses”.
The goal of this proposal is to expand the capabilities of an antiviral
screening process that utilizes incomplete viral genomes to identify
inhibitors of any biochemical pathway involved in viral genome replication
to be able to screen for multiple viruses.
Abstract
January 3, 2002
Apath On The Move
Apath, LLC will move to the
Nidus Center for Scientific Enterprise on January 3, 2002. Researchers
working on a host of RNA viruses will prosper in the new laboratory
environment. The Nidus Center is located at 893 North Warson Road, St.
Louis, MO 63141.
September 30, 2001
Apath Receives Phase II Grant From
The National Institutes of Health
Apath,
LLC received a 2 year, $750,000, grant from the National Institutes of
Health's National Institute of Allergy and Infectious Diseases under the
Small Business Innovation Research Program. The grant will help fund
current Apath studies of a potential new test for quantitating hepatitis C
virus in the blood of infected patients.
(St. Louis
Business Journal: October 26, page 9)
Abstract
back to top
